Invested and Greenebaums Honored with Plaque at Ceremony in March
Baltimore, Md. — March 19, 2013 — Kevin J. Cullen, M.D., has been named the first Marlene and Stewart Greenebaum Distinguished Professor in Oncology at the University of Maryland School of Medicine at a ceremony March 5. The ceremony also honored the Greenebaum family for their extraordinary generosity in supporting the world class oncology research and treatment program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. Dr. Cullen is Professor of Medicine at the University of Maryland School of Medicine and Director of the Greenebaum Cancer Center. The Greenebaums, owners of a real estate and development company, are longtime benefactors of the cancer center, which was named in their honor in the 1990s.
“On behalf of the Greenebaum family, I would like to thank everyone who has been involved in honoring our family,” says Michael Greenebaum. “We are very grateful to be a part of these great institutions. Under great leadership, we have watched them flourish and, more importantly, save lives. There is no bigger honor than to know that together we have made a difference. We are so pleased that Dr. Cullen is receiving the Marlene & Stewart Greenebaum Distinguished Professorship in Oncology. It is an honor to bestow him with this endowed professorship and to know that Dr. Cullen will be saving lives and spearheading groundbreaking research for years in the fight against cancer.”
In 1996, the Greenebaums made a $10 million gift to the University of Maryland School of Medicine and its partner University of Maryland Medical System. It was the largest private contribution ever made to the school or the hospital, and was made in recognition of “extraordinary growth and progress.” The gift came exactly five years after Marlene Greenebaum’s diagnosis of cancer in 1990, and it celebrated her successful treatment and recovery. In honor of the gift, the cancer center was named after the Greenebaums.
The Greenebaum Distinguished Professorship is the culmination of the family’s long history of affiliation with the University of Maryland. In the 1960s, doctors at the then-University Hospital successfully and compassionately treated Stewart Greenebaum’s father for a life-threatening condition. The lifesaving care sowed the seeds for Stewart and Marlene Greenebaum’s long-running support of the institution. Their commitments to the University of Maryland are extensive and diverse.
Mr. Greenebaum has played a prominent role in the growth of the institution. He is a member of the Board of Visitors of the University of Maryland School of Medicine, and both Greenebaums have served on the Cancer Center’s Board of Advisors since its inception in 1993. Mr. Greenebaum also joined the University of Maryland Medical System’s Board of Directors in 1990. He served as chairman from 1994 to 1998. Mr. Greenebaum also is a past Chairman of the Institute of Human Virology at the School of Medicine, where the Greenebaums created an annual Distinguished Scholar Lecture Series that has attracted world-wide recognition.
The Greenebaums also initiated the "Access to Medicine Fund," a program of scholarships for University of Maryland School of Medicine students who are residents of Maryland. Contributions from the Greenebaums and more than 50 of their friends support the fund. Michael Greenebaum has followed in his parents’ footsteps, continuing the family’s generosity toward the University of Maryland. Michael Greenebaum serves on the Board of Visitors of the University of Maryland School of Medicine and the cancer center’s Board of Advisors. He is also is the co-founder of the Maryland Half-Marathon, an annual fundraising event that has raised $1 million for the University of Maryland Greenebaum Cancer Center.
“The Greenebaums’ outstanding commitment to cancer research and treatment has made possible incredible growth in our program here at the University of Maryland School of Medicine,” says E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and John Z. and Akiko K. Bowers Distinguished Professor and Dean at the University of Maryland School of Medicine. “We are now a top-ranked oncology program with a National Cancer Institute designation. Our researchers are striving toward answers for patients and their families every day. The Greenebaums’ latest gift makes possible a professorship that will support the research, clinical, and administrative efforts of the University of Maryland Greenebaum Cancer Center in perpetuity. This professorship will allow the School of Medicine and the University of Maryland Medical Center to attract future leaders to perpetuate the advances we have seen under Dr. Cullen’s leadership. We are most grateful for the significant resources that the Greenebaums have given to our cancer center, and are honored to be able to recognize their generosity with this prominent plaque.”
Dr. Cullen is a renowned oncologist who specializes in head and neck cancer. He joined the University of Maryland in 2004, and under his leadership the cancer center achieved designation as a National Cancer Institute Cancer Center in 2008. The cancer center was ranked 11th out of 900 cancer programs nationwide in the 2012 U.S. News & World Report “Best Hospitals” list.
“I am so grateful to the Greenebaum family for all they have done for our center over time,” says Dr. Cullen. “None of our current success would be possible if not for their vision, engagement and support. This professorship is a great honor and I am delighted with the continued opportunity to work with our outstanding faculty and staff.”
Dr. Cullen is a highly regarded physician-scientist who is a member of the American Cancer Society National Board of Directors, the board of directors of the Association of American Cancer Institutes, and was appointed by President Obama as a member of the National Cancer Advisory Board. He earned his bachelor’s degree at Dartmouth College and his medical degree at Harvard Medical School. Dr. Cullen completed his internship and residency training at Beth Israel Hospital in Boston and received additional training at the National Cancer Institute. He served as interim director of the Lombardi Cancer Center at Georgetown University from 2000 to 2002, and was professor of medicine, oncology and otolaryngology at Georgetown.